SIIC MEDTECH<08018> - Results Announcement SIIC Medical Science and Technology (Group) Limited announced on 29/07/2003: (stock code: 08018 ) Year end date: 31/12/2003 Currency: HKD Auditors' Report: N/A Review of Interim Report by: Both Audit Committee and Auditors Important Note: This result announcement form only contain extracted information from and should be read in conjunction with the detailed results announcement of the issuer, which can be view on the GEM website at http://www.hkgem.com (Unaudited ) (Unaudited ) Last Current Corresponding Period Period from 01/01/2003 from 01/01/2002 to 30/06/2003 to 30/06/2002 Note ('000 ) ('000 ) Turnover 2 : 567,440 419,884 Profit/(Loss) from Operations : 98,544 88,462 Finance cost : (149) 0 Share of Profit/(Loss) of Associates : 18,780 16,208 Share of Profit/(Loss) of Jointly Controlled Entities : 470 (5) Profit/(Loss) after Tax & MI : 50,355 45,518 % Change over Last Period : +10.6 % EPS/(LPS)-Basic (in dollars) 3 : 0.0812 0.0734 -Diluted (in dollars) 3 : 0.0812 0.0729 Extraordinary (ETD) Gain/(Loss) : 0 0 Profit/(Loss) after ETD Items : 50,355 45,518 2nd Quarterly Dividend : N/A N/A per Share (Specify if with other : N/A N/A options) B/C Dates for 2nd Quarterly Dividend : N/A Payable Date : N/A B/C Dates for (-) General Meeting : N/A Other Distribution for : N/A Current Period B/C Dates for Other Distribution : N/A For and on behalf of SIIC Medical Science and Technology (Group) Limited Name : Wong Mei Ling, Marina Title : Company Secretary Responsibility statement The directors of the Company (the "Directors") as at the date hereof hereby collectively and individually accept full responsibility for the accuracy of the information contained in this results announcement form (the "Information") and confirm, having made all reasonable inquiries, that to the best of their knowledge and belief the Information are accurate and complete in all material respects and not misleading and that there are no other matters the omission of which would make the Information herein inaccurate or misleading. The Directors acknowledge that the Stock Exchange has no responsibility whatsever with regard to the Information and undertake to indemnify the Exchange against all liability incurred and all losses suffered by the Exchange in connection with or relating to the Information. Remarks: 1. Basis of preparation The principal accounting policies adopted in preparing the unaudited consolidated financial statements of the Group conform with accounting principles generally accepted in Hong Kong and accounting standards issued by the Hong Kong Society of Accountants. The consolidated financial statements have been prepared under the historical cost convention as modified for revaluation of certain properties and investments in securities. 2. Turnover Turnover represents the net amounts received and receivable for goods sold by the Group to outside customers during the period. For the period ended 30th June 2003 and 2002, the Group was engaged in the manufacture and sale of Chinese medicine and health supplement products. More than 90% of the Group's turnover, contribution to operating profit and assets was attributable to this business segment and located in the PRC. 3. Earnings per share The calculation of the basic and diluted earnings per share for the period is based on the following data: For the six months ended 30th June 2003 2002 Earnings: Net profit for the period and earnings for the purpose of basic and diluted earnings per share HK$50,355,000 HK$45,518,000 ============= ============= Number of shares : Weighted average number of ordinary shares for the purpose of basic earnings per share 620,005,470 620,000,000 Effect of dilutive potential ordinary shares - share options 122,943 4,071,419 ----------- ----------- Weighted average number of ordinary shares for the purpose of diluted earnings per share 620,128,413 624,071,419 =========== =========== 4. Change of figures reported for the last corresponding period To conform with current year's presentation of financal statements, the comparative figure for profit from operations was increased by HK$245,000 as the amortisation of goodwill on jointly controlled entities was not included in administrative expenses. |